We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Single-Dose Basiliximab Induction in Low-Risk Renal Transplant Recipients.
- Authors
Cunningham, Kathleen C.; Hager, David R.; Fischer, Jessica; D'Alessandro, Anthony M.; Leverson, Glen E.; Kaufman, Dixon B.; Djamali, Arjang
- Abstract
Objectives To compare the efficacy of a single dose of basiliximab with two doses in preventing acute rejection in selected low-risk renal transplant recipients. Methods This observational study of 760 kidney transplant recipients considered to be at low immunologic risk (peak panel reactive antibody less than 10%) compared patient and graft outcomes following a single-dose versus a two-dose regimen of basiliximab. Main Results No differences were found in patient survival (92% vs 92%, p=0.6), graft survival (86% vs 83%, p=0.2), acute rejection (cellular [4% vs 7%, p=0.2], antibody-mediated rejection [19% vs 19%, p=0.9]), or opportunistic infections (34% vs 30%, p=0.3) between the single versus two-dose regimens, respectively. In multivariate analyses, the number of doses of basiliximab was not associated with acute rejection or patient/graft survival despite adjustment with Cox regression and propensity scores. However, delayed graft function ( DGF), donor age older than 65 years, and human leukocyte antigen mismatch of 3 or higher were associated with acute rejection (hazard ratio [ HR] 2.64, 1.91, and 1.57, respectively, p≤0.04), and DGF and diabetes were associated with death/graft loss ( HR 2.56 and 1.63, respectively, p≤0.009). Principal Conclusions A single dose of basiliximab is safe and effective for induction in low-risk kidney transplant recipients.
- Subjects
BASILIXIMAB; KIDNEY transplant patients; DRUG dosage; IMMUNOLOGIC diseases; GRAFT rejection; DISEASE risk factors
- Publication
Pharmacotherapy, 2016, Vol 36, Issue 7, p823
- ISSN
0277-0008
- Publication type
Article
- DOI
10.1002/phar.1774